PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
This study is currently recruiting participants.
Verified February 2013 by UNC Lineberger Comprehensive Cancer Center
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01751516
First received: December 13, 2012
Last updated: February 19, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.
The primary purpose of this study is to determine the negative predictive value of PET/MRI for determining pathological complete response from neoadjuvant chemoradiation.
| Condition |
|---|
|
Rectal Carcinoma |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | PET/MRI as a Predictor for Response to Preoperative Radiation Therapy and Chemotherapy in Resectable Rectal Cancer: a Pilot Study. |
Resource links provided by NLM:
Further study details as provided by UNC Lineberger Comprehensive Cancer Center:
Primary Outcome Measures:
- Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology [ Time Frame: 4-8 weeks post-chemoradiation ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Recurrence-free survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Disease-specific survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Overall survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | October 2012 |
| Estimated Study Completion Date: | October 2018 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
UNC Hospitals
Criteria
Inclusion Criteria:
- Low-lying, low- to moderate-risk pathologically-confirmed rectal cancer (stage uT3n) or uT1-3N+
- Negative workup for distant disease
- > 18 years of age
- Pre-treatment workup completed including:
- history and physical
- CT or MRI of the abdomen and pelvis
- endoscopic tumor evaluation (biopsy, blood work to assess CEA and hematopoietic, renal and liver function)
- if female of child-bearing age, negative pregnancy test
- Recommendation to undergo preoperative concurrent chemoradiation, as determined by the treating physician
- Informed consent reviewed and signed
Exclusion Criteria:
- Not deemed a candidate for preoperative chemoradiation for medical reasons, such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or cardiac disease
- Hemoglobin ≤ 10.0 g/dL (transfusion allowed to achieve or maintain levels)
- ANC ≤ 1,500/cubic mm³
- Platelet count ≤ 100,000/mm³
- ALT and AST ≥ 2.5 times upper level of normal (ULN)
- Alkaline phosphatase ≥ 2.5 times ULN
- Total bilirubin ≥ 1.5 times ULN
- Creatinine clearance < 50 mL/min
- Creatinine ≥ 1.5 times ULN
- Not deemed a candidate for concurrent preoperative chemoradiation for social reasons, such as psychiatric illness
- Not deemed a surgical candidate
- Currently active second malignancy, except non-melanoma skin cancer, non-invasive bladder cancer, low risk adenocarcinoma of the prostate and carcinoma in situ of the cervix
- Previous pelvic radiation therapy
- History of severe reaction to gadolinium
- Inability to tolerate MRI (e.g., inability to lie flat for > 1 hour)
- Presence of a pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes
- Body Mass Index (BMI) > 35
- Pregnant or lactating female
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01751516
Contacts
| Contact: Dorothy A Riguera, BS | 919-843-5420 | riguera@email.unc.edu |
Locations
| United States, North Carolina | |
| University of North Carolina-Chapel Hill | Recruiting |
| Chapel Hill, North Carolina, United States, 27599 | |
| Contact: Dorothy Riguera, BS 919-843-5420 riguera@email.unc.edu | |
| Principal Investigator: Joel Tepper, MD | |
| Sub-Investigator: Z. Andrew Wang, MD | |
| Sub-Investigator: Seth Miller, MD | |
| Sub-Investigator: Benjamin Calvo, MD | |
| Sub-Investigator: Amir Khandani, MD | |
| Sub-Investigator: Bert O'Neil, MD | |
| Sub-Investigator: Kevin Greene, MD | |
| Sub-Investigator: W. Brian Hyslop, MD, PhD | |
| Sub-Investigator: David Lalush, PhD | |
Sponsors and Collaborators
UNC Lineberger Comprehensive Cancer Center
Investigators
| Principal Investigator: | Joel E Tepper, MD | University of North Carolina, Chapel Hill |
More Information
No publications provided
| Responsible Party: | UNC Lineberger Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01751516 History of Changes |
| Other Study ID Numbers: | LCCC1225 |
| Study First Received: | December 13, 2012 |
| Last Updated: | February 19, 2013 |
| Health Authority: | United States: Institutional Review Board United States: Data and Safety Monitoring Board |
Additional relevant MeSH terms:
|
Carcinoma Rectal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Colorectal Neoplasms Intestinal Neoplasms |
Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases |
ClinicalTrials.gov processed this record on May 22, 2013